GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reissued by Beaufort Securities in a note issued to investors on Monday. They presently have a GBX 1,800 ($23.75) price objective on the stock. Beaufort Securities’ price objective points to a potential upside of 18.46% from the company’s current price.

Several other equities analysts have also recently issued reports on GSK. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.07) price objective on shares of GlaxoSmithKline plc and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($21.25) price objective on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday. Morgan Stanley set a GBX 1,600 ($21.11) price objective on shares of GlaxoSmithKline plc and gave the stock a “sell” rating in a research note on Wednesday, October 18th. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Monday. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of GBX 1,676 ($22.12).

Shares of GlaxoSmithKline plc (GSK) traded down 0.26% during mid-day trading on Monday, hitting GBX 1519.50. 5,637,556 shares of the company’s stock traded hands. The stock has a 50 day moving average price of GBX 1,500.92 and a 200-day moving average price of GBX 1,578.36. The stock’s market cap is GBX 74.27 billion. GlaxoSmithKline plc has a 1-year low of GBX 1,444.00 and a 1-year high of GBX 1,724.50.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/glaxosmithkline-plc-gsk-rating-reiterated-by-beaufort-securities.html.

In other GlaxoSmithKline plc news, insider Manvinder Singh Banga bought 2,267 shares of GlaxoSmithKline plc stock in a transaction on Wednesday, July 26th. The stock was purchased at an average cost of GBX 1,599 ($21.10) per share, for a total transaction of £36,249.33 ($47,834.96). Also, insider Simon Dingemans bought 1,076 shares of GlaxoSmithKline plc stock in a transaction on Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Over the last 90 days, insiders have purchased 3,368 shares of company stock valued at $5,305,807.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.